ritanserin has been researched along with Chronic Kidney Failure in 1 studies
Ritanserin: A selective and potent serotonin-2 antagonist that is effective in the treatment of a variety of syndromes related to anxiety and depression. The drug also improves the subjective quality of sleep and decreases portal pressure.
ritanserin : A thiazolopyrimidine that is 5H-[1,3]thiazolo[3,2-a]pyrimidin-5-one which is substituted at position 7 by a methyl group and at position 6 by a 2-{4-[bis(4-fluorophenyl)methylidene]piperidin-1-yl}ethyl group. A potent and long-acting seratonin (5-hydroxytryptamine, 5-HT) antagonist of the subtype 5-HT2 (Ki = 0.39 nM), it is used in the treatment of a variety of disorders including anxiety, depression and schizophrenia. It has little sedative action.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The regular hemodialysis sessions every 2-3 days did not affect the elimination rate of ritanserin, as the terminal half-life in these patients (39 +/- 23 hr) is similar to that in healthy volunteers (41 +/- 14 hr)." | 2.67 | Pharmacokinetics of ritanserin in patients undergoing hemodialysis. ( Heykants, J; Huang, ML; Koch, S; Kokot, F; Kuska, J; Van Peer, A; Zazgornik, J, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zazgornik, J | 1 |
| Kuska, J | 1 |
| Kokot, F | 1 |
| Koch, S | 1 |
| Van Peer, A | 1 |
| Huang, ML | 1 |
| Heykants, J | 1 |
1 trial available for ritanserin and Chronic Kidney Failure
| Article | Year |
|---|---|
Pharmacokinetics of ritanserin in patients undergoing hemodialysis.
Topics: Administration, Oral; Adult; Female; Half-Life; Humans; Kidney Failure, Chronic; Male; Middle Aged; | 1991 |